SKYRIZI: Unpacking the Sales Forecast, Market Dynamics, and Strategic Outlook
As AbbVie's immunology portfolio continues to evolve in the post-Humira era, SKYRIZI (risankizumab) has emerged as one of the most closely watched biologic therapies in the global pharmaceutical landscape. Approved for moderate-to-severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis, this selective IL-23 inhibitor is reshaping treatment paradigms across multiple inflammatory conditions — and the financial story behind it is equally compelling.
